URGENT: This Altcoin Opportunity Won’t Wait – Act Now

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

Richard Chesworth net worth and biography

Richard Chesworth Biography and Net Worth

Insider of Kymera Therapeutics

Richard has more than 20 years of experience in the pharmaceutical and biotechnology industry and has contributed to the research and development programs of nine different compounds entering clinical trials including Tazverik™ which was recently approved for both epitheloid sarcoma and relapsed/refractory follicular lymphoma. Prior to joining Kymera as CSO, Richard was an Entrepreneur-In-Residence at Third Rock Ventures where he focused on building new drug discovery and development companies. Richard also served as Senior Vice President of Research at Epizyme, where he was responsible for pipeline activities from target selection to IND as well as non-clinical support of clinical candidates. Richard has also held positions at EnVivo (a.k.a. Forum Pharmaceuticals) Surface Logix, and, Pfizer. Richard obtained a BSc in Chemistry from Imperial College of Science, Technology and Medicine at the University of London and a DPhil in Chemistry from the University of Oxford.

What is Richard Chesworth's net worth?: The estimated net worth of Richard Chesworth is at least $1.37 million as of August 27th, 2021. Dr. Chesworth owns 33,779 shares of Kymera Therapeutics stock worth more than $1,373,454 as of December 21st. This net worth approximation does not reflect any other investments that Dr. Chesworth may own. Learn More about Richard Chesworth's net worth.
How do I contact Richard Chesworth?: The corporate mailing address for Dr. Chesworth and other Kymera Therapeutics executives is 200 Arsenal Yards Blvd. Suite 230, Watertown MA, 02472. Kymera Therapeutics can also be reached via phone at 857-285-5300 and via email at [email protected]. Learn More on Richard Chesworth's contact information.
Has Richard Chesworth been buying or selling shares of Kymera Therapeutics?: Richard Chesworth has not been actively trading shares of Kymera Therapeutics during the last ninety days. Most recently, Richard Chesworth sold 33,779 shares of the business's stock in a transaction on Friday, August 27th. The shares were sold at an average price of $60.12, for a transaction totalling $2,030,793.48. Following the completion of the sale, the insider now directly owns 33,779 shares of the company's stock, valued at $2,030,793.48. Learn More on Richard Chesworth's trading history.
Who are Kymera Therapeutics' active insiders?: Kymera Therapeutics' insider roster includes Jeffrey Albers (Director), Bruce Booth (Director), Richard Chesworth (Insider), Ellen Chiniara (Chief Legal Officer and Corporate Secretary), Jared Gollob (Insider), Bruce Jacobs (CFO), and Nello Mainolfi (CEO). Learn More on Kymera Therapeutics' active insiders.
Are insiders buying or selling shares of Kymera Therapeutics?: In the last twelve months, insiders at the sold shares 16 times. They sold a total of 1,008,191 shares worth more than $40,176,324.03. The most recent insider tranaction occured on September, 17th when Director Pamela Esposito sold 13,500 shares worth more than $651,780.00. Insiders at Kymera Therapeutics own 15.8% of the company. Learn More about insider trades at Kymera Therapeutics.
Information on this page was last updated on 9/17/2024.

Richard Chesworth Insider Trading History at Kymera Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/27/2021	Sell	33,779	$60.12	$2,030,793.48	33,779
8/17/2021	Sell	54,000	$50.37	$2,719,980.00	54,000

Richard Chesworth Buying and Selling Activity at Kymera Therapeutics

Kymera Therapeutics Company Overview

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Today's Range

Now: $40.66

$38.24

$40.78

50 Day Range

MA: $46.00

$39.06

$51.84

2 Week Range

Now: $40.66

$22.35

$53.27

Volume

1,145,939 shs

Average Volume

582,401 shs

Market Capitalization

$2.63 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.16

I was wrong. Dead wrong.

From Porter & Company | Ad

I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Here’s the full story for you.